Serotonin signaling pathway

The **serotonin signaling pathway** refers to a complex network involving synthesis, release, receptor binding, and reuptake/metabolism of serotonin (5-hydroxytryptamine or 5-HT), a monoamine neurotransmitter[1][4]. This biological process involves multiple molecular entities—primarily various subtypes of **serotonin receptors** (most are G protein-coupled receptors except for the ligand-gated ion channel 5-HT3)[7], as well as transporters and enzymes involved in serotonin metabolism. The effects mediated by this system include regulation of mood, cognition, sleep/wake cycles, gastrointestinal motility, cardiovascular homeostasis, and more[1][4]. Many pharmaceutical agents act on components within this system—such as selective serotonin reuptake inhibitors (SSRIs) that block reabsorption at synapses—but these drugs do not target "the serotonin signaling pathway" as a single entity[2][4]. The term "Serotonin signaling pathway" does not refer to a single molecule or therapeutic target but rather an entire physiological process involving many distinct druggable proteins. Therefore: > The entry "Serotonin signaling pathway" is **not** considered a valid therapeutic target itself; it is an umbrella term for numerous molecular targets such as specific serotonin receptor subtypes (e.g., 5‑HT2A receptor), transporter proteins (SERT), and metabolic enzymes. For structured data about drug targeting or biomarker use in this context you should focus on these individual molecules instead[6][7]. If you need information about one particular component—such as "Serotonin transporter," "5‑HT2A receptor," etc.—please specify that molecule for accurate structured data.

Other names

Serotonergic signaling5-HT signaling pathwayserotonin pathwayserotonergic system